Skip to content
DraconiticResearch
Search Sources API
186,125 studies31 sourcesUpdated just now
Peer-reviewedCC BY-NC-ND 4.0Australian Prescriber

Cardiac amyloidosis: recognition, diagnosis and management

  • Natasha Gorrie1,2
  • Elyn Montgomery3,2,4
  • Georgia McCaughan3,5,6
  • Antonia S Carroll3,7
  • Nicole K Bart3,2
7 affiliations
  1. 1The Prince Charles Hospital, Brisbane
  2. 2Victor Chang Cardiac Research Institute, Sydney
  3. 3St Vincent's Hospital Sydney
  4. 4University of Technology Sydney
  5. 5St Vincent's Private Hospital, Sydney
  6. 6University of New South Wales, Sydney
  7. 7Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney
Read full textPDFDOICite

Abstract

SUMMARY: Cardiac amyloidosis is an under-recognised but treatable condition characterised by insoluble protein deposition in the heart and is associated with high morbidity and mortality. It is most commonly caused by transthyretin (known as transthyretin [ATTR] amyloidosis) but may also be caused by a plasma cell dyscrasia (known as light chain [AL] amyloidosis).

Cardiac amyloidosis should be suspected in patients with heart failure and other suggestive features (e.g. carpal tunnel syndrome, peripheral and/or autonomic neuropathy), particularly in those aged over 65 years. Findings from a standard work-up for heart failure may raise the possibility of cardiac amyloidosis, such as unexplained cardiac biomarker elevation or left ventricular wall thickening on an echocardiogram.

Early investigation can begin in primary care. Monoclonal protein testing is essential to exclude AL amyloidosis, which requires urgent haematology review and treatment. Standard heart failure assessment should also be undertaken if not already performed. Patients with suspected cardiac amyloidosis should be promptly referred to a cardiologist or amyloidosis centre for confirmatory testing, which, in most cases, can be done noninvasively.

Treatment of ATTR includes disease-modifying therapies (tafamidis, vutrisiran) and heart failure management, predominantly with diuretics and sodium-glucose co-transporter 2 inhibitors. All patients with atrial fibrillation or atrial flutter should be anticoagulated regardless of CHA2DS2-VA score.

Early recognition, timely referral and multidisciplinary care are essential to improve outcomes.

Related

  1. A Progressive 99mTc-MDP Uptake in Transthyretin Cardiac Amyloidosis
    Satoshi Kurisu, Hitoshi Fujiwara, Kosuke Asano
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationJ-STAGE
  2. The Progressive Cardiac Uptake of 99mTc-MDP as a Clue to Transthyretin Amyloidosis
    Kazufumi Nakamura
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationJ-STAGE
  3. Effect of Transthyretin Stabilizer in Transthyretin Cardiac Amyloidosis
    Toru Kubo, Yuri Ochi, Yuichi Baba +1
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationJ-STAGE
  4. Gender and Racial Distribution of Transthyretin Stabilizer Therapy in Patients With Transthyretin Cardiac Amyloidosis.
    Stephen J Foley, Shruti Hegde
    JACC. AdvancesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCPMC
  5. Prevalence of amyloidosis among older cardiac patients with left ventricular hypertrophy: a cross-sectional single-centre study in Moscow, Russia.
    Tatiana Chernyshova, Dmitry Shchekochikhin, Kristina Charaya +8
    BMJ openPeer-reviewedCC BY-NCFull textMolecular biology & gene regulationEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{gorrie2026cardiac,
  title = {{Cardiac amyloidosis: recognition, diagnosis and management}},
  author = {Natasha Gorrie and Elyn Montgomery and Georgia McCaughan and Antonia S Carroll and Nicole K Bart},
  journal = {Australian Prescriber},
  year = {2026},
  month = oct,
  doi = {10.18773/austprescr.2026.039},
  url = {https://doi.org/10.18773/austprescr.2026.039},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Cardiac amyloidosis: recognition, diagnosis and management
AU  - Natasha Gorrie
AU  - Elyn Montgomery
AU  - Georgia McCaughan
AU  - Antonia S Carroll
AU  - Nicole K Bart
PY  - 2026
DA  - 2026/10/01
JO  - Australian Prescriber
DO  - 10.18773/austprescr.2026.039
UR  - https://doi.org/10.18773/austprescr.2026.039
AB  - SUMMARY: Cardiac amyloidosis is an under-recognised but treatable condition characterised by insoluble protein deposition in the heart and is associated with high morbidity and mortality. It is most commonly caused by transthyretin (known as transthyretin [ATTR] amyloidosis) but may also be caused by a plasma cell dyscrasia (known as light chain [AL] amyloidosis).  Cardiac amyloidosis should be suspected in patients with heart failure and other suggestive features (e.g. carpal tunnel syndrome, peripheral and/or autonomic neuropathy), particularly in those aged over 65 years. Findings from a standard work-up for heart failure may raise the possibility of cardiac amyloidosis, such as unexplained cardiac biomarker elevation or left ventricular wall thickening on an echocardiogram.  Early investigation can begin in primary care. Monoclonal protein testing is essential to exclude AL amyloidosis, which requires urgent haematology review and treatment. Standard heart failure assessment should also be undertaken if not already performed. Patients with suspected cardiac amyloidosis should be promptly referred to a cardiologist or amyloidosis centre for confirmatory testing, which, in most cases, can be done noninvasively.  Treatment of ATTR includes disease-modifying therapies (tafamidis, vutrisiran) and heart failure management, predominantly with diuretics and sodium-glucose co-transporter 2 inhibitors. All patients with atrial fibrillation or atrial flutter should be anticoagulated regardless of CHA2DS2-VA score.  Early recognition, timely referral and multidisciplinary care are essential to improve outcomes.
SN  - 0312-8008
SN  - 1839-3942
ER  -